TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
TCT 2022 – Edwards tries to Clasp an opportunity
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Intellia delivers a second knockdown success
Encouraging early results in hereditary angioedema join further progress in amyloidosis, but investors remain wary.
ISA 2022 – Alnylam takes heart from full Apollo-B data
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.
ESC 2022 – Preventicus gets halfway there
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
ESC 2022 – factor XI inhibitors crash
Development continues, but multi-billion dollar forecasts for this new anticoagulant class must now be in doubt.
